SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Karuna Therapeutics, Inc. (KRTX) , forward earnings yield 0.15%. PEG 1.01.
Criteria proven by this page:
- VALUE (10/100, Fail) — analyst consensus target implies downside from the current price ($257.50, 21.9%).
- Forward P/E 663.2
- PEG Ratio 1.01 — between 1.0–2.0 indicates moderate valuation relative to growth.
- Analyst consensus target $257.50 (-21.9% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 27/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
10/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — KRTX
Valuation Multiples
P/E (TTM)0.0
Forward P/E663.2
PEG Ratio1.01
Forward PEG1.01
P/B Ratio0.00
P/S Ratio18,639.45
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-11.73
Forward EPS (Est.)$0.50
Book Value / Share$0.00
Revenue / Share$0.02
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield0.15%
Dividend Yield0.00%
Analyst Target$257.50 (-21.9%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2017 |
$-0.81 |
$0.00 |
$-6.03M |
- |
| 2018 |
$-1.61 |
$0.00 |
$-17.51M |
- |
| 2019 |
$-3.75 |
$0.00 |
$-44.84M |
- |
| 2020 |
$-2.59 |
$0.00 |
$-68.55M |
- |
| 2021 |
$-4.94 |
$36.96M |
$-143.81M |
-389% |
| 2022 |
$-8.74 |
$10.64M |
$-276.34M |
-2597.9% |
| 2023 |
$-11.73 |
$654K |
$-433.68M |
-66311.9% |
